In This Article:
The Australian market has been experiencing a mixed performance, with the ASX200 down 0.75% at 8,140 points amid geopolitical tensions in the Middle East that have caused oil prices to surge. While the Energy sector has benefited from these developments, other sectors like Materials and Financials are facing declines, highlighting the importance of strategic stock selection during such volatile times. In this context, growth companies with high insider ownership can be appealing as they often indicate strong confidence from those closest to the business and may offer resilience in uncertain markets.
Top 10 Growth Companies With High Insider Ownership In Australia
Name | Insider Ownership | Earnings Growth |
Clinuvel Pharmaceuticals (ASX:CUV) | 10.4% | 27.4% |
Catalyst Metals (ASX:CYL) | 17% | 54.5% |
Genmin (ASX:GEN) | 12% | 117.7% |
Hillgrove Resources (ASX:HGO) | 10.4% | 71.5% |
AVA Risk Group (ASX:AVA) | 15.7% | 118.8% |
Pointerra (ASX:3DP) | 18.7% | 126.4% |
Liontown Resources (ASX:LTR) | 16.4% | 49.8% |
Acrux (ASX:ACR) | 17.4% | 91.6% |
Adveritas (ASX:AV1) | 21.1% | 144.2% |
Plenti Group (ASX:PLT) | 12.8% | 106.4% |
We'll examine a selection from our screener results.
Mineral Resources
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Mineral Resources Limited operates as a mining services company in Australia, Asia, and internationally, with a market cap of A$10.09 billion.
Operations: The company's revenue segments consist of A$3.38 billion from Mining Services, A$2.58 billion from Iron Ore, A$1.41 billion from Lithium, A$16 million from Energy, and A$19 million from Other Commodities.
Insider Ownership: 11.7%
Mineral Resources is experiencing significant earnings growth, forecasted at 38.3% annually, outpacing the Australian market. Despite trading at a discount to its estimated fair value and recent insider buying, profit margins have declined from last year. The company is exploring asset sales in the Perth Basin to strengthen its balance sheet amid high debt levels, with interest payments not well covered by earnings. Recent M&A activity could impact future financial positioning and growth strategies.
-
Dive into the specifics of Mineral Resources here with our thorough growth forecast report.
-
Our expertly prepared valuation report Mineral Resources implies its share price may be too high.
Mesoblast
Simply Wall St Growth Rating: ★★★★★☆
Overview: Mesoblast Limited is involved in the development of regenerative medicine products across Australia, the United States, Singapore, and Switzerland with a market cap of A$1.54 billion.